(UroToday.com) The AUA annual meeting’s evolving landscape of advanced prostate cancer treatment session included a talk by Dr. Deborah Kaye discussing the role of immunotherapy and PARP inhibitors. Dr. Kaye started by highlighting that there are currently numerous options for systemic treatment of mCRPC. As follows is a summary of the mCRPC first and second line options: